Stockreport

Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19 [Seeking Alpha]

Palvella Therapeutics, Inc.  (PVLA) 
PDF Pro forma cash of approximately $274 million as of December 31, 2025 reflects approximate net proceeds of $215.8 million from a February 2026 equity financing; cash and [Read more]